Compare Hyatt Hotels Corporation (H) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs TG Therapeutics Inc — how do they compare? Hyatt Hotels Corporation trades at $172.22 (market cap $16.27B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Hyatt Hotels Corporation is far larger — about 2.1× TG Therapeutics Inc's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| H | TGTX | |
|---|---|---|
Market Cap | $16.27B | $7.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $59.06 |
52-Week Low | $135.42 | $26.94 |
Enterprise Value | $20.17B | $7.84B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $178.25, up 4.8% over 24 hours, near its 52-week high of $206.86. The stock shows a bearish technical signal despite recent earnings beats, with Q2 2026 EPS of $1.12 surpassing the $0.913 estimate. Fundamentals reveal a high P/E ratio of 213.14 and thin net income margin of 1.1%, though revenue grew to $7.10B in 2025. Analyst consensus is a 'Hold' with a $199.55 price target, while recent news highlights valuation concerns amid fee growth and RevPAR gains.
Outlook is mixed: strong fee growth and a record pipeline support expansion, but high valuation, project delays, and debt pose risks. The stock offers potential from operational momentum, yet investors face headwinds from regional weakness and rich multiples. Net cash flow turned negative in 2025, underscoring financial pressure despite EBITDA growth.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
